Farallon Investment in Exelixis
Hedge Fund Presentation Collection
In 2023, Farallon Capital Management made a substantial investment in Exelixis, demonstrating strong confidence in the biotech company’s oncology-focused initiatives.
| Fund | Farallon |
| Target | Exelixis |
| Sector | Healthcare |
| Year | 2023 |
Farallon invested in Exelixis in 2023 and made public a presentation for it. If you are interested to learn about how hedge funds write presentations, here is one for you to learn from.
The Farallon Deck
This deck is in the public domain (Nothing privately shared is ever distributed on this site).
About the Exelixis deal
In 2023, Farallon Capital Management made a significant investment in Exelixis, a biotechnology company focused on cancer treatments. The investment involved acquiring a substantial stake in Exelixis, indicating Farallon’s confidence in the company’s potential for growth and development in the oncology sector. This move by Farallon highlights their strategic interest in the biotech industry and aligns with Exelixis’s ongoing efforts to expand its pipeline of cancer therapies.
About Farallon
Farallon Capital Management is an investment firm based in San Francisco, California. Founded in 1986 by Thomas Steyer and Donald Sussman, Farallon is known for its global investment strategies across a range of asset classes, including public equity, private equity, credit, and real estate. The firm manages assets for a variety of clients, including institutional investors, pension funds, foundations, and high-net-worth individuals. Over the years, Farallon has gained a reputation for its disciplined approach to investing and its ability to generate attractive returns while managing risk.
About Exelixis
Exelixis is a biotechnology company headquartered in Alameda, California. Founded in 1994, the company focuses on the discovery, development, and commercialization of novel medicines to treat cancer. Exelixis is best known for its flagship product, Cabometyx (cabozantinib), which is approved for the treatment of various types of cancer, including renal cell carcinoma and hepatocellular carcinoma. The company also has a pipeline of other promising oncology therapies in various stages of development. Exelixis collaborates with academic institutions, pharmaceutical companies, and other partners to advance its research and bring innovative treatments to patients in need.
Want to see more?
Head here to see the rest of the collection:
Comments (0)
There are no comments yet :(